Objective To compare the efficacy and safety of levetiracetam and topiramate plus tiapride in the treatment of refractory Tourette syndrome (TS) in children. Methods From January 2016 to February 2019,60 TS children aged 8～12 years were randomly divided into two groups. Because of the poor therapeutic effect of tiapride alone,the two groups were additionally given levetiracetam (LEV) and topiramate (TPM) respectively.Finally 49 childrencompleted the treatment for 8 weeks,of which,24 in levetiracetam group and 25 in topiramate group.Yale Global Tic Severity Scale (YGTSS) and Treatment Emergent Symptom Scale (TESS) were used to evaluate the effects and adverse reactions before and after treatment for 2,4,8 weeks. Results At the 2nd,4th and 8th weekend after treatment,YGTSS scores in LEV group and TPM group were lower than those before treatment,but YGTSS scores in TPM group were significantly lower than those in LEV group at each time period (t=4.185,7.787,10.521,P＜0.05). The effective rates of LEV group were 50.0%,54.2% and 45.8% at the end of 2,4 and 8 weeks,and those of TPM group were 76.0%,80.0% and 80.0% respectively.The effective rates of the TPM group at 2,4,and 8 weekends were 76.0%,80.0%,and 80.0%,respectively. The effective rate of the two groups at the end of the 8th week was significantly different (χ2=6.151,P<0.05). The incidence of adverse reactions in the LEV group and the TPM group were 12.5% and 16.0%,respectively (χ2=0.130,P>0.05). Conclusions Both LEV and TPM can be effectively applied to treat refractory TS in children. The short-term (8 weeks) efficacy of TPM is better than that of LEV. Both drugs have fewer short-term adverse reactions and tolerable.
Key words
levetiracetam /
topiramate /
Tourette syndrome /
efficacy /
adverse reactions /
short-term
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Stern JS,Burza S,Robertson MM.Gilles de la Tourette′s syn drome and its impact in the UK[J].Postgrad Med J,2005,81(951):12-19.
[2] 陈文雄,李斐.抽动障碍//金星明,静进.发育与行为儿科学[M].北京:人民卫生出版社,2014,12:493-499.
[3] Roessner V,Plessen KJ,Rothenberger A,et al.European clinical guidelines for Tourette syndrome and other tic disorders.Part Ⅱ:pharmacological treatment[J].Eur Child Adolesc Psychiatry,2011,20(4):173-196.
[4] Robertson MM,Eapen V,Cavanna AE.The international prevalence,epidemiology,and clinical phenomenology of Tourette syndrome:a cross-cultural perspective[J].J Psychosom Res,2009,67(6):475-483.
[5] Sullivan S,Rai D,Golding J,et al.The association between autism spectrum disorder and psychotic experiences in the Avon longitudinal study of parents and children (ALSPAC)birth cohort[J].J Am Acad Child Adolesc Psychiatry,2013,52(8):806-814.
[6] Quezada J,Coffman KA.Current approaches and new developments in the pharmacological management of Tourette syndrome[J].CNS Drugs,2018,32(1):33-45.
[7] 吴希如,林庆,包新华,等.小儿神经系统疾病基础与临床[M].北京:人民卫生出版社,2009:1050.
[8] 杨红英,黄清波,冯智.对比氟哌啶醇和托吡酯对小儿抽动障碍的疗效及安全性评价研究[J].哈尔滨医药,2018,38(1):56-57.
[9] 张宁,王振华,周俐红,等.左乙拉西坦添加治疗53例难治性部分性癫痫的临床效果及对认知功能的作用[J].临床医学,2015,35(9):52-53.
[10] Martínez-Granero MA,García-Pérez A,Montaes F. Levetiracetam as an alternative therapy for Tourette syndrome[J].Neuropsychiatr Dis Treat,2010,6:309-316.
[11] APA.Diagnostic and statistical manual of mental disorders,Fifth Edition(DSM-5)[M].Washington DC:American Psychiatry Association,2013:59-65.
[12] 张厚粲.韦氏儿童智力量表第四版(WISC-IV)中文版的修订[J].心理科学,2009,32(5):1177-1179.
[13] Ya-song DU,Hua-fang LI,Alasdair V,et al,Randomized do uble-blind multicentre placebo controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders[J].Aust N Z J Psychiatry,2008,42(9):807-813.
[14] 张明园.精神科评定量表手册[M].长沙:湖南科学技术出版社, 1998: 183-188.
[15] Felling RJ,Singer HS.Neurobiology of tourette syndrome:current status and need for further investigation [J].J Neurosci,2011,31(35):12387-12395.
[16] Kalanithi PS,Zheng W,Kataoka Y,et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome[J].Proc Natl Acad Sci U S A,2005,102(37):13307-13312.
[17] Lerner A,Bagic A,Simmons JM,et al.Widespread abnormality of theγ-aminobutyric acid-ergic system in Tourette syndrome[J].Brain,2012,135(Pt6):1926-1936.
[18] Draper A,Stephenson MC,Jackson GM,et al.Increased GA BA contributes to enhanced control over motor excitability in Tourette syndrome[J].Curr Biol,2014,24(19):2343-2347.
[19] Jackson GM,Draper A,Dyke K,et al.Inhibition,disinhibition,and the control of action in Tourette syndrome[J].Trends Cogn Sci,2015,19(11):655-665.
[20] 黄志民.托吡酯治疗顽固性小儿抽动障碍的临床观察[J].吉林医学,2017,38(8):1539-1540.
[21] Egunsola O,Choonaral I,Sammons HM.Safety of levetiracetam in paediatrics:a systematic review[J].PLoS One,2016,11(3):e0149686.
[22] Awaad Y,Michonb AM,Minarik S,et al.Levetiracetam in Tourette syndrome:a controlled double blind,placebo controlled study[J].J Pediatr Neurol,2009,76(9):253-263.
[23] 宋丽芳,陈国洪,王莉,等.左乙拉西坦治疗儿童多发性抽动症的疗效分析[J].海峡药学,2017,29(2):111-112.
[24] 中华医学会儿科学分会神经学组.儿童抽动障碍诊断与治疗专家共识(2017实用版)[J].中华实用儿科临床杂志,2017,32(15):1137-1139.
PDF(726 KB)
